Concord Biotech announced a robust start to FY27, with Q1 revenues reaching ₹257 crore, marking a healthy 26.2% year-on-year growth. The performance was broad-based across key product categories including immunosuppressants, anti-infectives, oncology, and antifungals. The company highlighted strong export growth of 46% and the commencement of commercial operations through its US-based distribution platform, Stellon Biotech.
Strong Q1 Performance Drives Growth
Concord Biotech has reported a significant start to the first quarter of FY27 (ended June 30, 2026), with revenues surging to ₹257 crore. This represents a substantial 26.2% increase compared to the same period last year, underscoring the company’s resilient performance despite previous year challenges.
Broad-Based Revenue Contributions
The growth in Q1 FY27 was characterized by its broad-based nature, with healthy contributions from all major product categories. Segments such as immunosuppressants, anti-infectives, oncology, and antifungals all played a role in the overall revenue uplift, rather than being driven by any single segment. This diversification in revenue streams indicates a healthy and sustainable business model.
Export Business Accelerates
The company’s export business continued to be a key growth driver, with export revenues showing an impressive 46% year-on-year increase in Q1 FY27. This growth was observed across various geographies, supported by rising inquiries from both major regulated and semi-regulated markets. Strengthening global regulatory approvals and a compliance framework have been instrumental in expanding the addressable market and deepening presence in existing geographies.
Strategic Milestones and Future Outlook
A notable milestone during the quarter was the commencement of commercial operations and sales through Stellon Biotech, Concord’s front-end distribution platform for formulation products in the U.S. While in its nascent stage, this initiative holds significant potential for future growth. The company also highlighted progress at its injectable facility, with advanced customer engagements expected to contribute to revenue and margin expansion.
Concord Biotech’s confidence in sustaining momentum is underpinned by its long-term growth strategy, niche capabilities in fermentation-based products, and leadership positions in key molecules. The company remains focused on scientific excellence, process innovation, and operational discipline to deliver consistent value to stakeholders.
Source: BSE
